Today: 20 March 2026
Subscribe
Browse Category

ASX:CSL 27 January 2026 - 7 March 2026

Australian Securities Exchange Weekly Wrap: ASX 200 Sheds A$130 Billion as Middle East War and Rate Risks Rattle Stocks

Australian Securities Exchange Weekly Wrap: ASX 200 Sheds A$130 Billion as Middle East War and Rate Risks Rattle Stocks

Australian shares lost 3.8% last week, erasing about A$130 billion in value as the Middle East conflict rattled markets. Miners fell 4.1%, gold miners 4.3%, while energy stocks rose 0.2% on surging oil prices. The Reserve Bank of Australia signaled a “live meeting” for March 17 as inflation risks mount. Economic growth beat forecasts, rising 0.8% in Q4.
7 March 2026
···
CSL share price slips again as buyback rolls on, March dividend date looms

CSL share price slips again as buyback rolls on, March dividend date looms

CSL Ltd shares closed down 1.5% at A$145.13 on Tuesday, extending a two-day slide to 5.3%. The company bought back 83,760 shares Monday for A$12.46 million, part of an ongoing US$750 million program. Interim CEO Gordon Naylor is leading after an 81% first-half profit drop and management changes. CSL’s interim dividend of US$1.30 a share goes ex-dividend March 10.
24 February 2026
·
CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL share price slips as buyback tally grows; Lilly deal sets up next week

CSL shares fell 0.6% to A$153.27 Friday, ending a two-day rebound. The company disclosed a 69,497-share buyback for A$10.7 million and confirmed a new licensing deal with Eli Lilly for clazakizumab, including a $100 million upfront payment. Director Alison Watkins acquired 214 shares under a board plan. Investors are watching buyback pace and updates on the Lilly agreement next week.
20 February 2026
····
ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%

ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%

The S&P/ASX 200 closed down 2.7 points at 8,867.40, as insurance brokers slumped on AI competition fears. CSL dropped 5% after announcing CEO Paul McKenzie's retirement. Treasury Wine Estates surged over 8% on a U.S. dispute settlement and upgraded earnings forecast. Investors await key earnings from Commonwealth Bank and CSL on Wednesday.
10 February 2026
······
CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

CSL share price in focus after ASX sell-off: what investors watch before Feb 11 results

CSL Limited shares closed down 0.4% at A$180.50 Friday as the S&P/ASX 200 dropped 2.03% to 8,708.80. CSL will report half-year results and announce its interim dividend on Feb. 11, with the stock set to trade ex-dividend March 10. A filing showed 59,992 CSL conditional rights lapsed this week. The company’s market value stands near A$87 billion, down about a third in the past year.
7 February 2026
···
CSL share price dips in ASX rout — here’s what investors are watching before earnings

CSL share price dips in ASX rout — here’s what investors are watching before earnings

CSL Limited fell 0.41% to A$180.50 as the S&P/ASX 200 dropped 2.03% to 8,709 points on Friday, marking the market’s worst day since November. About 1.23 million CSL shares changed hands ahead of its half-year results due Feb. 11. Healthcare stocks slipped 0.97%, while tech fell 3.7%. CSL reported 59,992 unquoted rights lapsed after processing January leavers, with a cessation date of Feb. 4.
6 February 2026
···
CSL Limited share price rises 2% on ASX — what to know ahead of Feb 11 results

CSL Limited share price rises 2% on ASX — what to know ahead of Feb 11 results

CSL shares rose 2.0% to A$181.70 on Wednesday, outperforming a flat health care sector as the ASX 200 gained 0.8%. Investors await CSL’s half-year results and interim dividend announcement on Feb. 11. The Reserve Bank of Australia raised rates to 3.85% this week, with another hike expected in May. CSL last cut its FY26 forecasts in October, citing weaker U.S. flu vaccination rates.
4 February 2026
·
CSL share price: Two dates now loom after Friday’s lift

CSL share price: Two dates now loom after Friday’s lift

CSL shares closed Friday at A$181.42, up 1.13%, as investors await half-year results and an interim dividend announcement on Feb 11. The RBA meets Feb 2–3, with its decision expected to influence rate expectations and market sentiment. The ASX 200 fell 0.7%, pressured by mining stocks, while healthcare outperformed.
1 February 2026
·
1 2 3 4

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop